Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap.

Using a preclinical screening cascade, we identified a pro-drug for a palindromic molecule with unique pharmacology (miridesap). The pro-drug depleted circulating SAP with a time course and extent similar to that of parenterally administered miridesap.